Chugai Gets Approval for Cancer Genomic Profile

Chugai Gets Approval for Cancer Genomic Profile

By, Admin 1 March 2024

Chugai obtains Japanese approval for FoundationOne CDx Cancer Genomic Profile to be used as a companion diagnostic for RET receptor tyrosine kinase inhibitor, selpercatinib for RET fusion-positive solid tumours

Chugai Pharmaceutical Co., Ltd. announced that it has obtained approval from the Ministry of Health, Labour and Welfare (MHLW) on February 28, 2024, for FoundationOne CDx Cancer Genomic Profile to be used as a companion diagnostic for Eli Lilly Japan K.K.’s RET (rearranged during transfection) receptor tyrosine kinase inhibitor, Retevmo capsules (generic name: selpercatinib), for RET fusion-positive solid tumours.

Words from Chugai

“We are pleased that FoundationOne CDx Cancer Genomic Profile was approved as a companion diagnostic for selpercatinib, a cancer therapeutic drug for a rare RET fusion gene. It is useful for smooth consideration of treatment plans for patients because it can diagnose with a single test, including extremely rare genetic mutations that are found to be expressed across cancer types,” said Chugai’s President and CEO, Dr. Osamu Okuda.

Impact of Approval

  • This approval enables the detection of RET fusion genes using the FoundationOne CDx Cancer Genome Profile to assist of the decision to use selpercatinib for RET fusion-positive solid tumours. 
  • The efficacy and safety of selpercatinib for RET fusion-positive solid tumours was evaluated in the LIBRETTO-001 phase 1/2 study. 
  • Eli Lilly Japan K.K. is currently applying to the MHLW for additional indications.

Chugai’s Commitment

As a leading company in the field of oncology, Chugai is committed to realizing advanced personalized healthcare in oncology and contributing to patients through the expansion of Comprehensive Genome Profile.

Intended Uses or Indications: 

The Product is used for comprehensive genomic profiling of tumor tissues in patients with solid cancers; The Product is used for detecting gene mutations and other alterations to support the assessment of drug indications listed in the table below.

Next Generation Solution

Developed by Foundation Medicine Inc., FoundationOne CDx Cancer Genomic Profile is a next-generation sequencing based in vitro diagnostic device for the detection of substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumour mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumour tissue specimens. The programme is available as a companion diagnostic for multiple molecular-targeted drugs approved in Japan.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!